It was less than a decade ago that most pharmaceutical manufacturers considered market access the last step in the commercialization process… maybe even something that happened post-launch! However it has become increasingly clear that this approach must change. Companies exploring opportunities in global markets face dynamic demographic and disease trends, changing market demands, and evolving regulatory requirements — all of which differ from one country to another. This complex environment makes planning for global market entry into both developed and developing countries a moving target.

Changing Payer Perspectives on Market Access Across the G-5 provides a timely analysis of the changing access and reimbursement environment in five of the most important markets in Europe, and how they serve as a model for other countries. This white paper outlines the evolving processes for reimbursement and pricing in each country, and the “rules” for establishing the “additional medical benefit” necessary to gain a price premium.

Illustrated by numerous candid interviews with payer “insiders” in each market and by recent case examples, this report will help you stay up to date regarding the real requirements and expectations of this complex and rapidly changing environment.